Cost-Effectiveness of Pembrolizumab vs. Docetaxel for Treatment of Previously Treated PD-l1 Positive Advanced NSCLC Patients
Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.2233
https://www.valueinhealthjournal.com/article/S1098-3015(16)33599-9/fulltext
Title :
Cost-Effectiveness of Pembrolizumab vs. Docetaxel for Treatment of Previously Treated PD-l1 Positive Advanced NSCLC Patients
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)33599-9&doi=10.1016/j.jval.2016.09.2233
First page :
A737
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
2120